PMID- 36331809
OWN - NLM
STAT- MEDLINE
DCOM- 20230425
LR  - 20230517
IS  - 1460-2180 (Electronic)
IS  - 0143-3334 (Print)
IS  - 0143-3334 (Linking)
VI  - 43
IP  - 12
DP  - 2022 Dec 31
TI  - LncRNA GAS5 regulates the Wnt/beta-catenin pathway through the 
      miR-18a-5p/AXIN2/GSK3beta axis to inhibit the proliferation and migration of bladder 
      cancer cells.
PG  - 1176-1189
LID - 10.1093/carcin/bgac087 [doi]
AB  - LncRNA growth arrest specific 5 (GAS5) has been confirmed to play an essential 
      role in a number of biological processes, such as tumor regulation and gene 
      transcription. GAS5 has been shown to be a tumor suppressor gene in many types of 
      cancer, but its specific mechanism of action in bladder cancer (BC) remains to be 
      elucidated. In this study, we explored the biological properties of GAS5 in BC 
      and its mechanism of action in BC. We analyzed the expression of GAS5 in 50 pairs 
      of BC tissues and found that GAS5 was low expressed in BC tissues compared with 
      normal mucosal tissues. In vitro and in vivo experiments showed that GAS5 could 
      affect the proliferation and migration of BC cells. Nucleoplasmic isolation 
      assays and fluorescence in situ hybridization (FISH) assays demonstrated the 
      localization of GAS5 in cell cytoplasm. Chromatin isolation by RNA purification 
      (ChIRP), RNA immunoprecipitation (RIP) and luciferase assay demonstrated the 
      target binding relationship of GAS5 with miR-18a-5p. Rescue experiments 
      demonstrated that GAS5 promoted the proliferation and migration of BC cells 
      through target binding of miR-18a-5p. Moreover, miR-18a-5p bound to its targets 
      AXIN2 and GSK3beta, which in turn affected the expression of Wnt/beta-catenin 
      pathway-related proteins. Our findings demonstrate that GAS5 regulates 
      Wnt/beta-catenin pathway activity by regulating the miR-18a-5p/AXIN2/GSK3beta axis to 
      modulate BC progression, providing a new potential therapeutic strategy for the 
      treatment of BC.
CI  - (c) The Author(s) 2022. Published by Oxford University Press.
FAU - Zhang, Ze
AU  - Zhang Z
AUID- ORCID: 0000-0001-6335-6491
AD  - Department of Urology, The Fifth Affiliated Hospital Sun Yat-sen University, 
      Zhuhai, Guangdong Province, 519000, P. R. China.
AD  - Department of Urology, The First Affiliated Hospital of Wannan Medical College 
      (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
AD  - Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher 
      Education Institution (Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
FAU - Liu, Tiantian
AU  - Liu T
AUID- ORCID: 0000-0002-8654-9912
AD  - Department of Urology, The Fifth Affiliated Hospital Sun Yat-sen University, 
      Zhuhai, Guangdong Province, 519000, P. R. China.
AD  - Department of Urology, The First Affiliated Hospital of Wannan Medical College 
      (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
AD  - Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher 
      Education Institution (Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
FAU - Cheng, Chao
AU  - Cheng C
AD  - Department of Urology, The Fifth Affiliated Hospital Sun Yat-sen University, 
      Zhuhai, Guangdong Province, 519000, P. R. China.
AD  - Department of Urology, The First Affiliated Hospital of Wannan Medical College 
      (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
AD  - Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher 
      Education Institution (Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
FAU - Wang, Jiawei
AU  - Wang J
AD  - Department of Urology, The First Affiliated Hospital of Wannan Medical College 
      (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
AD  - Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher 
      Education Institution (Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
FAU - Wang, Chong
AU  - Wang C
AD  - Department of Urology, The First Affiliated Hospital of Wannan Medical College 
      (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
AD  - Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher 
      Education Institution (Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
FAU - Huang, Houbao
AU  - Huang H
AD  - Department of Urology, The First Affiliated Hospital of Wannan Medical College 
      (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui Province, 241000, 
      China.
FAU - Li, Yawei
AU  - Li Y
AD  - Department of Urology, The Fifth Affiliated Hospital Sun Yat-sen University, 
      Zhuhai, Guangdong Province, 519000, P. R. China.
AD  - Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong 
      Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated 
      Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, P. R. 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (beta Catenin)
RN  - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)
RN  - 0 (AXIN2 protein, human)
RN  - 0 (Axin Protein)
RN  - 0 (MIRN18A microRNA, human)
SB  - IM
MH  - Humans
MH  - *MicroRNAs/genetics/metabolism
MH  - *RNA, Long Noncoding/genetics/metabolism
MH  - beta Catenin/genetics/metabolism
MH  - Glycogen Synthase Kinase 3 beta/genetics/metabolism
MH  - In Situ Hybridization, Fluorescence
MH  - *Urinary Bladder Neoplasms/genetics
MH  - Cell Proliferation/genetics
MH  - Cell Line, Tumor
MH  - Gene Expression Regulation, Neoplastic
MH  - Cell Movement/genetics
MH  - Axin Protein/genetics/metabolism
PMC - PMC10122427
COIS- The authors declare that they have no conflict of interest.
EDAT- 2022/11/05 06:00
MHDA- 2023/04/25 10:20
PMCR- 2022/11/04
CRDT- 2022/11/04 12:23
PHST- 2022/06/30 00:00 [received]
PHST- 2022/10/18 00:00 [revised]
PHST- 2022/11/04 00:00 [accepted]
PHST- 2023/04/25 10:20 [medline]
PHST- 2022/11/05 06:00 [pubmed]
PHST- 2022/11/04 12:23 [entrez]
PHST- 2022/11/04 00:00 [pmc-release]
AID - 6798911 [pii]
AID - bgac087 [pii]
AID - 10.1093/carcin/bgac087 [doi]
PST - ppublish
SO  - Carcinogenesis. 2022 Dec 31;43(12):1176-1189. doi: 10.1093/carcin/bgac087.